While it rarely contains KRAS mutations, it shows RAS pathway activation in about 25% of tumors [8,9] and KRAS amplification in 13.9% of patients, especially in HGSOC patients, who represent the prototypical type II ovarian cancer [5,9]. This evidence concerns the gene KRAS and ovarian carcinoma.